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Abstract
Background: We examined the therapeutic potential of a proprietary Croton palanostigma extract
(Zangrado®) in the management of emesis and itch.
Methods: Emesis was induced in ferrets with morphine-6-glucuronide (0.05 mg/kg sc) in the
presence of Zangrado (3 mg/kg, ip) and the cannabinoid receptor 1 antagonist, AM 251 (5 mg/kg,
ip). Topical Zangrado (1%) was assessed for anti-pruretic actions in the 5-HT-induced scratching
model in rats and evaluated in capsaicin-induced gastric hyperemia as measured by laser doppler
flow. In the ApcMinmouse model of precancerous adenomatosis polyposis, mice received Zangrado
(100 μg/ml in drinking water) from the age of 6 – 16 weeks for effects on polyp number. In RAW
264.7 cells Zangrado was examined for effects on lipopolysaccharide-induced nitrite production.
Results: Zangrado was a highly effective anti-emetic, reducing morphine-induced vomiting and
retching by 77%. These benefits were not associated with sedation or hypothermia and were not
reversed by cannabinoid receptor antagonism. Itch responses were blocked in both the morphine
and 5-HT models. Zangrado did not exacerbate the ApcMincondition rather health was improved.
Capsaicin-induced hyperemia was blocked by Zangrado, which also attenuated the production of
nitric oxide by activated macrophages.
Conclusion: Zangrado is an effective anti-emetic and anti-itch therapy that is devoid of common
side-effects, cannabinoid-independent and broadly suppresses sensory afferent nerve activation.
This complementary medicine represents a promising new approach to the management of nausea,
itch and irritable bowel syndrome.
Introduction
The latex of the Amazonian traditional medicine Croton
palanostigma  and related Croton  species is traditionally
used in the treatment of inflammation, pain, itch, and a
number of gastrointestinal afflictions that are common in
the rainforest [1]. This traditional medicine is derived
from a fast growing tree that is known by different names
in various countries: in Peru it is called sangre de grado
and in Ecuador, sangre de drago. We have found substan-
tial scientific support for a number of these ethnomedical
applications [2-4]. A central component of these benefits
centers on its ability to suppress the activation of primary
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afferent nerves, supplemented by transcription-based and
direct anti-inflammatory mechanisms of action [2-4]. The
present investigation is focused on the utility of Zan-
grado®, an extract of Croton palanostigma, in treatment of
emesis and itch.
While nausea and vomiting can severely affect the quality
of life, there have been few therapeutic advances in its
management in recent years and these conditions remain
therapeutic challenges [5-10]. Itch may be considered as a
cutaneous equivalent of nausea in terms of the involve-
ment of primary afferent nerves, and is similarly lacking in
new treatments [11]. The current pharmaceutical options
in the treatment of nausea and vomiting are invariably
associated with side-effects reflecting their actions on the
central nervous system [5-7]. Perhaps not surprisingly
given the restricted therapeutic options and high inci-
dence of complications there is a high use of complemen-
tary medicines in this patient population [5]. An effective
approach that is devoid of central nervous system compli-
cations remains elusive.
Cannabinoids have been a recent focus of potential ther-
apeutic breakthroughs [8,12,13]. Cannabinoids are effec-
tive anti-emetics and analgesic agents. However, central
nervous system complications, including sedation, hypo-
thermia and other cognitive complications, remain a chal-
lenge [14]. In addition, the societal and legal issues that
surround cannabinoids are not easy to overcome. The
present investigation was designed to address the poten-
tial anti-emetic benefits of Zangrado by examining its
actions in the presence of cannabinoid receptor antago-
nism, and by exploring its actions on various agents that
activate primary afferent nerves.
Methods
Production and standardization of Zangrado
Zangrado was produced from the latex of the Peruvian
medicinal plant, sangre de grado, by Rainforest Nutrition-
als, Inc. (Raleigh, NC). This proprietary technique yields
an extract that is standardized for proanthocyanidin con-
tent (minimum of 100 mg/g) that is comprised of short-
chain oligomers, less than 6 mer, as recently described [4].
Opioid-Induced emesis in ferrets
Adult ferrets (900–1500 g, Mustela putoris furo, Marshall
Research Labs, NY) were used and all experiments were
conducted in accordance with the guidelines established
by the Canadian Council on Animal Care and were
approved by the University of Calgary Health Sciences
Animal Care Committee. Animals were fasted overnight
before experimentation.
Two series of experiments were performed. One focused
on morphine-6-glucuronide (M6G) induced emesis,
defined as episodes of vomiting and retching, and the
other protocol compared the effects of Zangrado with
WIN 55,212-2, a cannabinoid receptor 1 (CB1) agonist,
on body temperature and sedation.
Zangrado (3 mg/kg, ip), the CB1 receptor antagonist, AM
251 (5 mg/kg, ip, Tocris, Ballwin, MO) or vehicle (2%
dimethyl sulfoxide and 1% Tween 80 in physiological
saline), were administered 15 minutes prior to the emetic
agent M6G (0.05 mg/kg, sc, Lipomed, Arlesheim, Switzer-
land). Emesis was then measured for the next 60 minutes.
The majority of emetic episodes occur within the first 10
minutes after M6G administration and the 60 min proto-
col duration is sufficient to capture all emetic episodes.
Itch, like nausea and vomiting, is a common side-effect of
opioid narcotics. In ferrets M6G treatment evokes a lick-
ing response with a similar time-course to vomiting and
retching. It is not clear if this response reflects a response
related to vomiting e.g., nausea, or rather does it mimic
itch. Both sensations are difficult to model. While there is
uncertainty as to what the licking response reflects it was
nevertheless quantified.
In a separate series of experiments, the CB1 receptor ago-
nist, WIN 55,212-2 (Tocris, Ballwin, MO) or Zangrado
was administered to ferrets in the absence of M6G to
quantify their effects on body temperature and ambula-
tion. Hypothermia and sedation are common effects of
cannabinoids. The dose of WIN 55,212-2 (1 mg/kg, ip)
had previously been shown to suppress the emetic effects
of M6G, an effect which is blocked by AM 251 at the dose
used in the current M6G protocol (Van Sickle et al 2001,
Simoneou et al 2001). Body temperature was measured
rectally at 30 and 45 minutes after administration of WIN
55,212-2 or Zangrado. Ambulation was not quantified,
but observational notes were taken.
Scratching evoked by intradermal serotonin
As with the ferret studies, rat protocols were conducted in
accordance with the guidelines established by the Cana-
dian Council on Animal Care and were approved by the
University of Calgary Health Sciences Animal Care Com-
mittee. Adult male Sprague Dawley rats who had previ-
ously had the fur clipped and shaved from the nape of the
neck, received a subcutaneous injection of serotonin (5-
HT, 100 μg) to evoke scratching behavior [15], with saline
injections used as the sham control. Serotonin-evoked
scratching is regarded as a reliable model of itch [16,17],
in contrast histamine does not evoke this behavior in rats
[16-18].
A time course response where the number of scratching
episodes following subcutaneous 5-HT (2%, 10 μl) was
determined over the course of a 1 hour observation period
as previously described [15]. This was followed by twoJournal of Translational Medicine 2008, 6:3 http://www.translational-medicine.com/content/6/1/3
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investigational protocols. In the first protocol 50 μl of a
1% Zangrado crème in a base of Dermabase (Glaxo) was
applied either 30 min prior to the administration of 5-HT,
or immediately after 5-HT administration. In the second
protocol topicals were applied after immediately after the
5-HT injection, and a 1% Zangrado crème was compared
to a commercial hemorrhoid crème (Preparation H®,
American Home Products) or vehicle alone. Topicals (50
μl) was gently rubbed into the skin at the 5-HT injection
site. Rats were then placed in individual cages to facilitate
video-recording of behavior (in the absence of laboratory
personnel) for 60 minutes. The frequency of scratching
episodes was quantified by an individual unaware of the
treatments the rats had received as previously described
[15].
Capsaicin-induced gastric hyperemia
As previously described [3], gastric blood flow was meas-
ured by a laser Doppler flow meter placed on the gastric
luminal surface of anesthetized, laparotomized rats. This
involves the use of a plexiglas chamber used for isolating
the mucosal surface while maintaining the neural and vas-
cular supply intact. The luminal surface is continually
bathed in a buffered salt solution. After a 15 min baseline
recording of blood flow capsaicin (320 μM) alone, or con-
taining Zangrado (0.2 mg/ml) was added. Hyperemia is
expressed as a percentage change from baseline.
Murine familial adenomatosus polyposis (FAP) as a model 
of colon cancer
Min/+ (C57BL/6J-ApcMin) and wild type (C57BL/6J) mice
were purchased from Jackson Laboratories (Bar Harbor,
ME). Mice were housed in a room with a 12 hour light-
dark cycle and had free access to food (LabDiet®, Prolab®
RMH 3500, Purina Mills, Inc., St. Louis, MO) and water
during the entire protocol. All procedures were approved
by the Albany Medical College Institutional Animal Care
and Use Committee (IACUC).
Min/+ mice were treated for a period of 10 weeks either
with vehicle (water) or Zangrado in drinking water at a
concentration of 100 μg/ml. This concentration was cho-
sen because a previous study showed that the parent tradi-
tional medicine, the latex of Croton palanostigma,
effectively healed gastric ulcers in rodents via this route of
administration at 20 or 200 μg/ml [2], without affecting
behavior or drinking habits. Fluid intake and body
weights were recorded every three days, with fluid intake
calculated based on the number of mice per cage.
Treatment commenced at 6 weeks of age and concluded at
16 weeks of age. Following completion of the treatment
period, mice were euthanized with sodium pentobarbital
(Nembutal®, 50 mg/kg im.) and the entire gastrointestinal
(GI) tract removed. The gastrointestinal tract was segre-
gated into stomach, small intestine, and colon, and placed
into 10% phosphate buffered formalin for fixation.
Following a 24 hour fixation period, the stomach and
intestines were opened longitudinally and rinsed with
phosphate buffered saline (PBS, pH 7.4). Tissues were
pinned flat on wax blocks, covered with trypan blue
(0.4% solution) for 10 minutes and rinsed with PBS to
improve polyp contrast. Polyp numbers were determined
by manually counting via a dissecting microscope (Bausch
and Lomb, Rochester, NY) by an observer unaware of the
treatment protocol for that preparation.
LPS-Induced nitrite production
Lipopolysaccharide (LPS) induction of nitric oxide pro-
duction by macrophages, reflecting the up-regulation of
inducible nitric oxide gene expression, was quantified as
nitrite accumulation [19]. Cells (2.5 × 105) were placed
into 24 well plates and allowed to adhere overnight. Fol-
lowing the overnight incubation, the old media was aspi-
rated and new media containing the test compounds and
LPS (E. coli serotype 026:B6) were added (final volume
per well equal to 1 ml). Cells were pre-incubated with the
test compounds for 30 minutes, followed by a 24 hour
exposure to LPS (2 ng/ml). Nitrite concentration was
determined from an aliquot of the supernatant. Superna-
tant solutions were mixed with an equal volume of Griess
reagent (1% sulfanilamide, 0.1 % napthylethylene
diamine dihydrochloride, 5% phosphoric acid) and
nitrite content measured spectrophotometrically at a 540
nm (reference wavelength 650 nm). Nitrite concentration
was then extrapolated from a standard curve generated
with sodium nitrite. Cell viability was determined via the
MTT assay.
Cell and culture conditions
Murine macrophages (Raw 264.7) cells were maintained
in Dulbecco's modified Eagle medium (DMEM) with fetal
bovine serum (10%), 4.5 g/L D-glucose, 4 mM L-
glutamine, 25 mM HEPES and 1.5 g/L sodium bicarbo-
nate. Culture medium contained 40 μg/ml penicillin G,
40 μg/ml streptomycin and 0.1 μg/ml amphotericin B.
Culture media was replaced every three days and cell lines
were subcultured weekly with trypsin. Cells were incu-
bated in a humidified chamber at an atmosphere of 5%
CO2 and 37°C. Culture reagents were purchased from
Mediatech, Inc (Herndon, VA).
Statistical evaluation
Data is presented as mean ± SEM with annotation as to the
n value. Comparisons between groups for simple paired
comparisons were made with a Students' t-test. However,
if there was more than one group the data was initially
examined by ANOVA, and if significant then an appropri-
ate multiple comparison test was used (Dunnett's or Bon-Journal of Translational Medicine 2008, 6:3 http://www.translational-medicine.com/content/6/1/3
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ferroni). Significance was taken at a p value of less than
0.05.
Results
Emesis and Itch induced by morphine-6-glucuronide
Ferrets respond to M6G with a rapid and reproducible
emetic response (vomiting and retching) that typically
abates within 10 minutes. Previously, we have shown that
this response is suppressed by CB1 receptor agonism and
enhanced by CB1 receptor antagonism [20,21]. At the
dose of 3 mg/kg, Zangrado was a remarkably effective
anti-emetic reducing episodes of vomiting and retching in
M6G treated ferrets by 77% (Figure 1). Co-administration
of the CB1 receptor antagonist, AM 251, failed to reverse
this response, although the number of episodes did
increase. However, the magnitude of this AM 251 effect
was comparable to what we have previously observed in
the M6G model with AM 251 in the absence of Zangrado.
In other words, AM 251 significantly raises emetic epi-
sodes in M6G treated ferrets because it blocks the anti-
emetic tone exerted of endogenous cannabinoids [20].
The number of licking episodes, was reduced by 87% with
Zangrado (Fig. 2). This effect was not reversed by AM 251.
To further compare the anti-emetic actions of Zangrado
with cannabinoids and to evaluate the potential side-
effects of Zangrado, we compared Zangrado and the CB1
receptor agonist WIN 55,212-2 on ferret body tempera-
ture and motility. Using a dose of WIN 55,212-2 previ-
ously shown to suppress M6G-induced emesis [20-22],
we noted a profound and sustained hypothermic
response (Figure 3). However, in Zangrado treated ferrets
body temperature remained unaltered. Ambulation was
not directly quantified as an index of sedation, but subjec-
tive measurements were clear-cut. Ferrets treated with
WIN 55-212-2 lay essentially motionless in their cages
during the observation period. In contrast, Zangrado
treated ferrets displayed a normal playful movements and
freely explored their environment and performed groom-
ing behaviors.
Scratching evoked by subcutaneous 5-HT
Local administration of 5-HT evokes a scratching response
at the site of the injection that peaks within 10 minutes
and then slowly declines over the course of the 60 minute
observation period (Figure 4). By contrast saline did not
evoke a scratching response.
Topical administration of Zangrado (1%) was effective in
suppressing the number of scratching episodes induced
by 5-HT (Figure 5). There was a significantly greater reduc-
tion in the scratching response when Zangrado was
administered 30 minutes prior to 5-HT administration
versus immediately after 5-HT (p < 0.05), but both were
effective anti-pruretic regimens (p < 0.05) compared to
vehicle. When evaluated against a commercially available
hemorrhoid crème (Preparation H) as an anti-pruretic
Suppression of morphine-6-glucuronide-induced vomiting  and retching in ferrets with Zangrado, and the effects of CB1  receptor antagonism with AM 251 Figure 1
Suppression of morphine-6-glucuronide-induced vomiting and 
retching in ferrets with Zangrado, and the effects of CB1 recep-
tor antagonism with AM 251. Ferrets treated with the opioid narcotic, 
morphine-6-glucuronide (M6G) display a substantial emetic response with 
on average over 12 episodes per hour. Zangrado administration (3 mg/kg 
ip) 15 minutes prior to M6G resulted in a 77% reduction in emetic epi-
sodes (n = 6, P < 0.01). Co-administration of Zangrado with the CB recep-
tor antagonist, AM 251 (5 mg/kg, ip) failed to reverse the anti-emetic 
effects of Zangrado (n = 6). The slight increase in emetic episodes with 
AM 251 is comparable to that seen with ferrets treated with AM 251 
alone and is thought to reflect the anti-emetic effects of endogenous can-
nabinoids [20,21].
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Suppression of morphine-6-glucuronide-induced licking in  ferrets with Zangrado, and the effects of CB1 receptor inhibi- tion of AM 251 Figure 2
Suppression of morphine-6-glucuronide-induced licking in ferrets 
with Zangrado, and the effects of CB1 receptor inhibition of AM 
251. Ferrets treated with M6G display a licking response which was quan-
tified. Treatment with Zangrado (3 mg/kg, ip) reduced this licking response 
by 87% (n = 6, P < 0.01). Co-treatment with AM 251, the CB1 receptor 
antagonist, failed to reverse the benefits of Zangrado on M6G-induced itch 
(n = 6).
0
2
4
6
8
10
12
14
16
18
20
0
2
4
6
8
10
12
14
16
18
20
L
i
c
k
i
n
g
 
 
 
e
p
i
s
o
d
e
s
/
h
r
Morphine-6-Glucuronide Treatment
Control
Zangrado 3 mg/kg
Zangrado + AM 251
*
*Journal of Translational Medicine 2008, 6:3 http://www.translational-medicine.com/content/6/1/3
Page 5 of 10
(page number not for citation purposes)
therapy, both agents significantly reduced the total
number of scratching episodes (Figure 6) with the Zan-
grado being slightly more effective although this differ-
ence was not statistically significant.
Gastric hyperemia induced by topical capsaicin
Capsaicin applied topically to the gastric mucosal surface
resulted in a marked increase in local blood flow (Fig. 7).
Zangrado administered as a pretreatment (0.2 mg/kg) was
able to completely prevent this hyperemia response.
Anti-pruretic effects between Zangrado and a commercial  hemorrhoid crème Figure 6
Anti-pruretic effects between Zangrado and a commercial hem-
orrhoid crème. Subcutaneous 5-HT administration (black column, n = 
11) evoked a significant scratching response over saline (control, *** p < 
0.001). This scratching response was significantly attenuated by either top-
ical administration of Preparation H (Prep H, purple column, * p < 0.01, n 
= 7) or Zangrado (red column, ** p < 0.001, n = 10), when applied imme-
diately after the administration of 5-HT.
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Time course of the scratching response to subcutaneous 5- HT Figure 4
Time course of the scratching response to subcutaneous 5-HT. 
Number of episodes of scratching in 5-min intervals over a one-hour 
period after injection of 5HT subcutaneously. (n = 5 per group) Controls 
got an injection of an identical volume of saline (100 μl).
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Comparison of the cannabinoid receptor agonist, WIN  55,212-2 and Zangrado on body temperature in ferrets Figure 3
Comparison of the cannabinoid receptor agonist, WIN 55,212-2 
and Zangrado on body temperature in ferrets. Ferrets treated with 
the CB1 receptor agonist, WIN 55,212-2 (1 mg/kg, ip) displayed a substan-
tial reduction in body temperature when measured at 30 and 45 minutes 
after administration. In contrast, there was no effect of Zangrado (3 mg/kg, 
ip) on body temperature (n = 6, p < 0.05). Both agents were administered 
at effective anti-emetic doses.
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Effects of Zangrado on 5-HT evoked scratching: Comparison  between pretreatment and immediate post-treatment Figure 5
Effects of Zangrado on 5-HT evoked scratching: Comparison 
between pretreatment and immediate post-treatment. Scratching 
episodes in response to saline injection (control, n = 5) and 5-HT (black 
column, n = 11) with vehicle treatment (50 μl of Dermabase crème) or the 
effects of 50 μl of zangrado (1%) crème applied 30 min (-30 Min column, n 
= 10) before the sc injection of 5-HT or immediately after (0 Min column, 
n = 8). The statistical difference between groups is noted in the figure.
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Effects of chronic Zangrado in ApcMin/+mice
The  ApcMin/+murine model of FAP and colon cancer is
characterized by the development of a large number of
polyps in the small and large intestine [23]. Given that
Zangrado may be potentially used to control nausea and
emesis in cancer patients, we elected to determine the
impact that Zangrado may have on polyp development in
this model. Weight gain in ApcMin/+mice is compromised
as a result of their condition. When Zangrado was added
to the drinking water (100 μg/ml) for 10 weeks beginning
at 6 weeks of age, there was a tendency for an improve-
ment in weight gain (Figure 8). At necropsy the number of
polyps in Zangrado treated ApcMin/+mice was reduced
compared to control mice (Figure 9). Both the changes in
weight gain and polyp number failed to reach statistical
significance, but this may reflect the small n values in this
evaluation for a model with inherent variability. 
LPS-induced nitrite production by macrophages
Murine macrophages treated with LPS accumulated nitrite
in the media as previously described, reflecting the induc-
tion of inducible nitric oxide synthase gene expression
[19]. Treatment with Zangrado resulted in a suppression
of nitrite levels (p < 0.05, Figure 10)
Discussion
These results indicate that Zangrado, a proprietary extract
of the Amazonian medicinal plant Croton palanostigma [4]
is an effective anti-emetic agent in the opioid-induced
model in ferrets. Indeed, in this regard it is remarkably
potent given that it is a natural product and not pure sin-
gle chemical entity and administered at 3 mg/kg. The
magnitude of this anti-emetic action is substantial, even
when compared to pure cannabinoid agonists [20,21]
administered at comparable doses (1 mg/kg). Beyond effi-
cacy it is indeed important to note that severe sedation
Polyp number in control or Zangrado treated ApcMin/+mice Figure 9
Polyp number in control or Zangrado treated ApcMin/+mice. Apc-
Min/+mice treatment with Zangrado (100 μg/ml in drinking water, n = 5) 
displayed a 26% reduction in the number of polyps when compared to 
vehicle control mice (n = 10). This trend was not statistically significant. 
There were no polyps noted in wild type mice.
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Effect of Zangrado on capsaicin-induced gastric hyperemia in  rats Figure 7
Effect of Zangrado on capsaicin-induced gastric hyperemia in 
rats. Capsaicin (320 μM) applied to the luminal surface of intact gastric 
mucosa results in a hyperemia as measured by laser Doppler flow. Rats 
pretreated with luminal Zangrado (0.2 mg/kg) ablated this hyperemia 
response (n = 5, P < 0.01).
Body Weight in ApcMin/+mice over a 10 week treatment  period with Zangrado or vehicle Figure 8
Body Weight in ApcMin/+mice over a 10 week treatment period 
with Zangrado or vehicle. Body weight (mean ± sem) of ApcMin/+mice 
determined over a 10 week treatment period is shown for mice treatment 
with Zangrado (n = 5, 100 μg/ml in drinking water) or unaltered drinking 
water (control). The Zangrado treated mice displayed a greater body 
weight over this period than did control mice (n = 10). This trend was not 
statistically significant.
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that accompanies cannabinoid-based anti-emetic actions
were completely absent with Zangrado.
This opioid narcotic model of emesis is also associated
with licking response, which may reflect itch, another
characteristic complication of post-operative narcotic
analgesia. Zangrado was similarly effective in blocking
both emesis and licking in response to morphine. Both
itch and nausea/emesis are mediated by primary afferent
nerves, and morphine is thought to promote both sensa-
tions secondary to spinal disinhibition of suppressive of
pain pathways [11]. These are troubling complications of
post-operative narcotic analgesia [9] and the present
results suggest that Zangrado may represent a new
approach to improved patient care.
Cannabinoids can also attenuate both itch, emesis and
nausea [12-14,20-22] and given the phytoceutical nature
of cannabinoids and Zangrado it was deemed important
to evaluate if the effects of Zangrado were mediated by
cannabinoid receptors. However, AM 251, the CB1 recep-
tor antagonist, failed to block the anti-emetic or anti-lick-
ing effects of Zangrado in the M6G model were blocked
(Figures 1 and 2). We have previously reported that this
dose of AM 251 is effective in preventing the anti-emetic
actions of the cannabinoid agonist WIN 55,212-2 [20].
From this we conclude that Zangrado's anti-emetic
actions are not mediated by CB1 receptors. The slight
increase in emetic and licking episodes with AM 251 is
consistent with an action on endogenous cannabinoids
and independent of Zangrado's actions.
Additionally treatment of naïve ferrets with the CB1 recep-
tor agonist WIN 55,212-2, administered at an effective
anti-emetic dose [20-22], caused a series of significant and
characteristic side-effects, specifically sedation and hypo-
thermia (Figure 3). In contrast, Zangrado failed to alter
body temperature, motility and behavior. These results set
Zangrado apart from cannabinoid-based approaches.
Primary afferent nerves are responsible for transmitting
the sensations of pain, itch and nausea, with the latter
being organ-specific responses. Recently it has been dem-
onstrated that primary afferent fibers that mediate the sen-
sation of itch as opposed to pain [24,25], represent a
separate subclass of these nerves. This finding was in keep-
ing with the knowledge that opioid narcotics could block
pain and spinal responses to capsaicin but yet evoke itch
and nausea, as reproduced in this study [9]. Counter-irri-
tancy has also been a therapeutic approach to itch to man-
age the dominance of one symptom but is ultimately a
less than desirable approach to treating these conditions.
Previously we had demonstrated that Croton palanostigma
latex was an effective analgesic and inhibitor of neuro-
genic inflammation [2,3]. This was extended to Zangrado
in the present study where gastric hyperemia induced by
mucosal capsaicin administration was blocked. It is well
appreciated that capsaicin's hyperalgesia and vascular
actions result from the activation of primary afferent
nerves via the transient receptor potential vanilloid recep-
tor 1 (TRPV1) and this action suggests that Zangrado has
a local action to limit sensory afferent neural activity.
Indeed, we had noted that Croton palanostigma blocked
inflammatory events (hyperalgesia, edema, vasodilation)
induced by a diversity of agonists for primary afferent
nerves, including capsaicin, PGE2 and protease activated
receptor-2, recently implicated in the pathophysiology of
irritable bowel syndrome [26]. This suggests that primary
afferent nerves are the likely target for this traditional
medicine. This interpretation is extended in the present
study where the itch response to both morphine and sub-
cutaneous 5-HT were blocked despite their central versus
local nervous system origins. It is uncommon for a thera-
peutic agent to block pain, itch and nausea, and strongly
suggests that these benefits result from a broad suppres-
sion of primary afferent nerve activity and not an effect on
a specific subset of nerves (emesis versus pain, or itch ver-
sus pain). Irritable bowel syndrome (IBS) is a major gas-
trointestinal disorder that remains poorly managed.
Nevertheless as it is well accepted that a critical and driv-
ing component of the disease is an overly reactive primary
afferent nervous innervation of the gut [26], the calming
actions of Zangrado on this neural network may represent
a potential therapeutic breakthrough that should be
explored.
Effects of Zangrado on the production of nitrite by LPS-acti- vated macrophages Figure 10
Effects of Zangrado on the production of nitrite by LPS-activated 
macrophages. Murine macrophages, Raw 264.7 cells, treated with LPS (2 
ng/ml) displayed a marked increase in nitrite production. Co-administra-
tion of Zangrado with LPS resulted in a significant reduction in nitrite pro-
duction (n = 6, p < 0.05).Journal of Translational Medicine 2008, 6:3 http://www.translational-medicine.com/content/6/1/3
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The lack of sedative effects or hypothermia associated
with Zangrado's benefits further supports the concept that
benefits are directed at the peripheral and not central
nervous system. Generally, the current options for treating
nausea and vomiting possess a central nervous system
mechanism of action [8]. Agents that solely operate via
peripheral actions are generally less effective (glucose, gin-
ger). Further support for a peripheral site of action for
Zangrado is evident in a small clinical study where the
parent traditional medicine was applied topically to vari-
ous insect bites, stings and plant reactions [3]. In this
study analgesic, anti-pruretic and other anti-inflammatory
benefits were apparent within minutes of topical admin-
istration (1% solution) when applied after the event, sim-
ilar to the present rat model of pruritis evoked by 5-HT.
The rapidity of these benefits on topical application sug-
gests a local action and is consistent with the traditional
use of the medicinal plant in the Amazon rainforest where
such afflictions are commonplace [1]. The other tradi-
tional use is for severe gastrointestinal events – nausea,
ulcers, cramping and diarrhea. In our previous studies
with Croton palanostigma, we noted improved gastric ulcer
healing, suppression of neurogenic intestinal electrolyte
fluxes, analgesia, and anti-inflammatory actions consist-
ent with the traditional applications for the parent medic-
inal plant [2,3]. Indeed, it appears that suppression of
neurogenic inflammation is an important component of
these actions.
There are results that suggest that the traditional medicine
possesses additional actions, which is not unexpected
given that this is not a single chemical entity. The acceler-
ated gastric ulcer healing in response to Croton pal-
anostigma was accompanied with lowered expression of
various pro-inflammatory genes [2]. This included induc-
ible nitric oxide synthase, which is supported with the
lowered macrophage production of nitrite in the present
study and consistent with a redox-based modification of
transcriptional events. With its high proanthocyanidin
content, Zangrado is an exceptional antioxidant. A related
extract progrado, which is enriched for log chain proan-
thocyanidin oligomers as opposed to short chain oligom-
ers in Zangrado, has a number of anti-inflammatory and
reparative actions that reflect transcriptional actions [4].
Progrado was effective in protecting human cartilage from
the destructive effects of interleukin-1β, while promoting
the expression of the anabolic repair factor, IGF-1. In
addition, progrado can completely inhibit the gelatino-
lytic actions of matrix metalloproteinase 2 and 9 [4].
Standardization of botanical extracts is always of concern,
as there is a potential for mixed results with different sam-
ples reflecting production, geographical or seasonal influ-
ences. As the precise chemical entities responsible for
these actions are unknown we need to design a standard-
ization process that is meaningful and reliable. For this
extract we choose proanthocyanidin content and nature,
specifically a proanthocyanidin content of > 100 mg/g,
which is substantial, and composed of short-chain oli-
gomers [4]. It is important to note that we have no
encountered any definable variation in bioactivity over
region and time in our investigations over the course of
some years. Complex chemical extracts that constitute
complementary medicines like Zangrado and Progrado by
virtue of their mixed composition can provide a plethora
of actions. In theory these various components may (a)
enhance therapeutic potential, (b) exert independent
actions or (c) potentially cancel benefits. Nevertheless, the
anti-emetic and anti-pruretic actions in the present report
suggest that Zangrado is not only effective but possesses
characteristics that offer advantages over current therapeu-
tic options.
The ApcMin/+murine model of colon cancer [23] was cho-
sen for evaluation because nausea and emesis are signifi-
cant factors in the management of cancer, chemotherapy
and palliative medicine in general [10]. In these states it is
important that any therapy does not exacerbate the can-
cerous state while alleviating the symptoms, hence the
evaluation in the Min/+ model of familial adenomatous
polyposis. We have previously observed that the Croton
palanostigma promotes apoptosis in a variety of gastroin-
testinal cancer cell culture lines [27] suggesting that it may
be a source of new oncological therapies. However, it was
important to take these in vitro observations into a more
complex animal model. The ApcMin/+mice studies showed
improvements in weight gain and polyp number, and
although encouraging these results did not reach statisti-
cal significance. Nevertheless, it was clear that Zangrado
did not exacerbate the condition. By comparison the 28%
reduction in polyp number with Zangrado was more
effective than our previous observations with aspirin [28],
a proposed colon cancer chemopreventative agent [29],
which was associated with a 3% increase in polyp number
and no improvement in animal weight gain. Proanthocy-
anidins, polyphenols that are exceptionally enriched in
Zangrado, have been suggested to be potential chemo-
therapeutic agents in various cell lines [30], indicating
that this chemical class may contribute to the actions of
Zangrado. It is therefore tantalizing to consider that Zan-
grado may be a source of chemotherapeutic agents or
adjuvants that also block nausea and emesis as opposed to
promoting these adverse conditions. Safety is always an
issue with the application of traditional medicines from
outside cultures. In the case of Zangrado, the data is con-
sistent with safe applications, as noted here with the
chronic administration in ApcMin/+mice, as well as previ-
ous studies using OECD safety and toxicity tests where it
was awarded the highest safety rating with no detectable
toxicity at 2000 mg/kg on acute oral administration [4].Journal of Translational Medicine 2008, 6:3 http://www.translational-medicine.com/content/6/1/3
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This is framed by the impressive potency of Zangrado as
an anti-emetic, anti-pruretic agent and its ability to sup-
press primary afferent nerve activation in the present
study. These mechanism of action results are entirely con-
sistent with the low amounts Croton palanostigma used
ethnomedically by cultures in tropical South America to
manage these symptoms. We therefore contend that these
mechanisms are the most likely explanations for the ben-
efits of this traditional medicine, and because these
actions are distinct from current treatment options Zan-
grado may represent a new and exciting approach to these
conditions.
Conclusion
Zangrado is a proanthocyanidin rich complementary
medicine that has potent anti-emetic and anti-itch actions
that are independent of cannabinoid receptors and appear
to reflect actions on the peripheral nervous system, specif-
ically primary afferent nerves. The paucity of side-effects
that burden other anti-emetics suggest that Zangrado may
be a useful therapeutic option to improve the quality of
life for a variety of afflictions and complications where
afferent nerve traffic is problematic including nausea, itch,
chemotherapy, motion sickness, irritable bowel syn-
drome and palliative medicine.
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